177Lu-PD-29875
/ PeptiDream
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 13, 2025
Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models.
(SNMMI 2025)
- "To assess biodistribution, 64Cu-PD-29875, 177Lu-PD-29875 or 225Ac-PD-29875 was dosed to BxPC3-CLDN18.2 xenograft mice, and the percentage of injected dose per gram of tissue in tumors and major organs was quantified by cut and count method. PD-29875 is a promising radiotheranostic peptide for CLDN18.2-expressing solid tumors including pancreatic cancer."
Clinical • Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18
May 11, 2025
Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models.
(SNMMI 2025)
- "PD-29875 is a promising radiotheranostic peptide for CLDN18.2-expressing solid tumors including pancreatic cancer."
Clinical • Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18
March 26, 2025
First-in-class Claudin 18.2 targeting radiopeptide, 64Cu-PD-29875 and 177Lu-PD-29875, exhibit promising theranostic potential in a pancreatic cancer xenograft model
(AACR 2025)
- "PD-29875 has preferable properties for imaging and therapy with radionuclides for theranostic use in CLDN18.2 expressing solid tumors including pancreatic cancer."
Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18
1 to 3
Of
3
Go to page
1